Recent Advances in Immunomodulatory Therapy in Sepsis: A Comprehensive Review

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 May 1

PMID 38690455

Authors

Abhishek Jain

Amol Singam

V N K Srinivas Mudiganti

Affiliations

Soon will be listed here.

Abstract

Sepsis remains a critical healthcare challenge, characterized by dysregulated immune responses to infection, leading to organ dysfunction and high mortality rates. Traditional treatment strategies often fail to address the underlying immune dysregulation, necessitating exploring novel therapeutic approaches. Immunomodulatory therapy holds promise in sepsis management by restoring immune balance and mitigating excessive inflammation. This comprehensive review examines the pathophysiology of sepsis, current challenges in treatment, and recent advancements in immunomodulatory agents, including biologics, immunotherapy, and cellular therapies. Clinical trial outcomes, safety profiles, and future research and clinical practice implications are discussed. While immunomodulatory therapies show considerable potential in improving sepsis outcomes, their successful implementation requires further research, collaboration, and integration into standard clinical protocols.

Citing Articles

Critical Insights into Novel Immunomodulatory Therapy for Sepsis: Evaluating Promise Amidst Limitations.

Angadi V, Kambagiri P, Jindal A Indian J Crit Care Med. 2025; 29(1):90.

PMID: 39802260 PMC: 11719545. DOI: 10.5005/jp-journals-10071-24847.

The toxic effects of neutrophil extracellular traps on mesenchymal stem cells.

Aghayan A, Mirazimi Y, Nasehi L, Atashi A Mol Biol Rep. 2024; 52(1):30.

PMID: 39614028 DOI: 10.1007/s11033-024-10134-2.

The Role of Mycobacterium indicus pranii in Sepsis Management: A Comprehensive Review of Clinical Outcomes and Therapeutic Potential.

Dhande D, Dhok A, Anjankar A, Nagpure S, Ganjare R Cureus. 2024; 16(8):e66772.

PMID: 39268263 PMC: 11392011. DOI: 10.7759/cureus.66772.

References

Strzelec M, Detka J, Mieszczak P, Sobocinska M, Majka M . Immunomodulation-a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. Front Immunol. 2023; 14:1127704. PMC: 10033545. DOI: 10.3389/fimmu.2023.1127704. View

Steinhagen F, Schmidt S, Schewe J, Peukert K, Klinman D, Bode C . Immunotherapy in sepsis - brake or accelerate?. Pharmacol Ther. 2020; 208:107476. DOI: 10.1016/j.pharmthera.2020.107476. View

Wu X, Jiang J, Gu Z, Zhang J, Chen Y, Liu X . Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress. Stem Cell Res Ther. 2020; 11(1):345. PMC: 7414268. DOI: 10.1186/s13287-020-01855-9. View

Li Y, Ji M, Yang J . Current Understanding of Long-Term Cognitive Impairment After Sepsis. Front Immunol. 2022; 13:855006. PMC: 9120941. DOI: 10.3389/fimmu.2022.855006. View

Zhuang W, Lin Y, Su L, Wu M, Jeng H, Chang H . Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications. J Biomed Sci. 2021; 28(1):28. PMC: 8043779. DOI: 10.1186/s12929-021-00725-7. View

Marshall J, Vincent J, Guyatt G, Angus D, Abraham E, Bernard G . Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Crit Care Med. 2005; 33(8):1708-16. DOI: 10.1097/01.ccm.0000174478.70338.03. View

Ono S, Tsujimoto H, Hiraki S, Aosasa S . Mechanisms of sepsis-induced immunosuppression and immunological modification therapies for sepsis. Ann Gastroenterol Surg. 2018; 2(5):351-358. PMC: 6139715. DOI: 10.1002/ags3.12194. View

Gyawali B, Ramakrishna K, Dhamoon A . Sepsis: The evolution in definition, pathophysiology, and management. SAGE Open Med. 2019; 7:2050312119835043. PMC: 6429642. DOI: 10.1177/2050312119835043. View

Marques A, Torre C, Pinto R, Sepodes B, Rocha J . Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms. J Clin Med. 2023; 12(8). PMC: 10142733. DOI: 10.3390/jcm12082892. View

10.

Schinkel M, Nanayakkara P, Wiersinga W . Sepsis Performance Improvement Programs: From Evidence Toward Clinical Implementation. Crit Care. 2022; 26(1):77. PMC: 8951662. DOI: 10.1186/s13054-022-03917-1. View

11.

Vincent J, Sun Q, Dubois M . Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis. 2002; 34(8):1084-93. DOI: 10.1086/339549. View

12.

Slim M, van Mourik N, Dionne J, Oczkowski S, Netea M, Pickkers P . Personalised immunotherapy in sepsis: a scoping review protocol. BMJ Open. 2022; 12(5):e060411. PMC: 9086601. DOI: 10.1136/bmjopen-2021-060411. View

13.

Rudd K, Kissoon N, Limmathurotsakul D, Bory S, Mutahunga B, Seymour C . The global burden of sepsis: barriers and potential solutions. Crit Care. 2018; 22(1):232. PMC: 6151187. DOI: 10.1186/s13054-018-2157-z. View

14.

Regmi S, Pathak S, Kim J, Yong C, Jeong J . Mesenchymal stem cell therapy for the treatment of inflammatory diseases: Challenges, opportunities, and future perspectives. Eur J Cell Biol. 2019; 98(5-8):151041. DOI: 10.1016/j.ejcb.2019.04.002. View

15.

Hmadcha A, Martin-Montalvo A, Gauthier B, Soria B, Capilla-Gonzalez V . Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy. Front Bioeng Biotechnol. 2020; 8:43. PMC: 7013101. DOI: 10.3389/fbioe.2020.00043. View

16.

Hansel T, Kropshofer H, Singer T, Mitchell J, George A . The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010; 9(4):325-38. DOI: 10.1038/nrd3003. View

17.

Choudhary R . Sepsis Management, Controversies, and Advancement in Nanotechnology: A Systematic Review. Cureus. 2022; 14(2):e22112. PMC: 8918265. DOI: 10.7759/cureus.22112. View

18.

Gupta S, Basu S, Soni V, Jaiswal R . Immunotherapy: an alternative promising therapeutic approach against cancers. Mol Biol Rep. 2022; 49(10):9903-9913. PMC: 9244230. DOI: 10.1007/s11033-022-07525-8. View

19.

Bascones-Martinez A, Mattila R, Gomez-Font R, Meurman J . Immunomodulatory drugs: oral and systemic adverse effects. Med Oral Patol Oral Cir Bucal. 2013; 19(1):e24-31. PMC: 3909428. DOI: 10.4317/medoral.19087. View

20.

Jain K . Personalized Immuno-Oncology. Med Princ Pract. 2020; 30(1):1-16. PMC: 7923844. DOI: 10.1159/000511107. View